OTIC Otonomy Inc.

1.95
-0.05  -3%
Previous Close 2
Open 2.02
Price To Book 1.49
Market Cap 60,087,711
Shares 30,814,211
Volume 67,952
Short Ratio
Av. Daily Volume 166,171
Stock charts supplied by TradingView

NewsSee all news

  1. Otonomy Provides Business Update Related to COVID-19 Pandemic

    SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a business update related

  2. Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière's diseaseCurrent capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO,

  3. Otonomy to Present at Two Upcoming Investor Conferences

    SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D.,

  4. Otonomy to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update

    SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial

  5. Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program

    SAN DIEGO, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial has been paused due to COVID-19.
OTO-413
Hidden hearing loss
Phase 3 data released August 30 failed to meet primary and key secondary endpoints.
OTO-104 AVERTS-1
Meniere's disease
Phase 1/2 data due 2Q 2020.
OTO-313
Tinnitus
Additional Phase 3 trial data due 3Q 2020.
OTIVIDEX
Ménière's disease
Approved December 11, 2015
OTIPRIO (ciprofloxacin otic suspension)
Ear Tube Placement Surgery
Approval announced March 2, 2018.
OTIPRIO
Acute otitis externa

Latest News

  1. Otonomy Provides Business Update Related to COVID-19 Pandemic

    SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a business update related

  2. Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière's diseaseCurrent capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. ET SAN DIEGO,

  3. Otonomy to Present at Two Upcoming Investor Conferences

    SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D.,

  4. Otonomy to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update

    SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial

  5. Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program

    SAN DIEGO, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from

  6. Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

    SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at

  7. Otonomy Provides Corporate and Product Pipeline Update

    Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière's disease Current capital funds operations into 2021 SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Otonomy,

  8. Otonomy to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D.,

  9. Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière's diseaseBroadest pipeline in neurotology field expanded to include gene therapy collaboration targeting most common

  10. Otonomy to Report Third Quarter 2019 Financial Results and Provide Corporate Update

    SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial

  11. AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss

    GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of

  12. Otonomy to Present at the Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber,

  13. Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss

    SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase